SCHEMBL3368267

SCHEMBL3368267

N#CC(C#N)=Cc1cccc(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
KMT2A Q03164 5/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 4/20 0.54
KDM4E B2RXH2 3/20 0.54
LMNA P02545 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
POLB P06746 1/20 0.54
NFE2L2 Q16236 3/20 0.52
EGFR P00533 4/20 0.52
MAPK1 P28482 3/20 0.52
CYP3A4 P08684 3/20 0.52
THPO P40225 3/20 0.52
BLM P54132 3/20 0.52
PMP22 Q01453 3/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2D6 P10635 2/20 0.52
TP53 P04637 2/20 0.52
CYP2C9 P11712 2/20 0.52
HPGD P15428 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30729660 1.00 MAPT (0.54) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL5865768 0.86 ALDH1A1 (0.65) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL26552233 0.81 MAPT (0.54) MAPTLMNANFE2L2MAPK1CYP3A4
SCHEMBL8543873 0.78 EGFR (0.64) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL2556610 0.78 ENPP2 (0.60) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL20615263 0.78 KDM4E (0.69) MAPTKMT2AALDH1A1KDM4EPOLB
SCHEMBL28791205 0.78 KDM4E (0.69) MAPTKMT2AALDH1A1KDM4EPOLB
SCHEMBL30457529 0.77 KMT2A (0.56) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL3368556 0.77 KMT2A (0.54) MAPTKMT2AALDH1A1MEN1KDM4E
SCHEMBL17466928 0.77 ALDH1A1 (0.54) MAPTKMT2AALDH1A1MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118287150-A Method for efficiently catalyzing Knoevenagel condensation reaction by porphyrin and quaternary ammonium salt synergistic catalytic system 沈阳药科大学 2024-07-05 CN disclosed
CN-117623983-A Method for constructing cyclopentene skeleton by directly cyclizing allyl alcohol 南京工业大学 2024-03-01 CN disclosed
EP-3553097-B1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORP (JP) 2022-05-04 EP disclosed
US-11225540-B2 Copolymer and optical film using same TOSOH CORPORATION (JP) 2022-01-18 US disclosed
CN-110248971-B Copolymer and optical film using the same 东曹株式会社 2021-11-02 CN disclosed
EP-3172272-B1 MODIFIED HETEROPHASIC POLYOLEFIN COMPOSITION MILLIKEN & CO (US) 2020-11-25 EP disclosed
US-20200095358-A1 COPOLYMER AND OPTICAL FILM USING SAME TOSOH CORPORATION (JP) 2020-03-26 US disclosed
EP-3553097-A1 COPOLYMER AND OPTICAL FILM USING SAME Tosoh Corporation (JP) 2019-10-16 EP disclosed
CN-110248971-A Copolymer and the optical film for using the copolymer 东曹株式会社 2019-09-17 CN disclosed
US-9410035-B2 Modified heterophasic polyolefin composition MILLIKEN & COMPANY (US) 2016-08-09 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed
EP-0537949-B1 Antiproliferative derivatives of 4H-naphtho 1,2-b pyran LILLY CO ELI (GB) 1998-07-01 EP disclosed
US-5284868-A Naphthopyran derivatives; for autoimmune diseases, cancer ELI LILLY AND COMPANY (US) 1994-02-08 US disclosed
US-5281619-A Administering naphtho(1,2-B)pyran derivatives ELI LILLY AND COMPANY (US) 1994-01-25 US disclosed
EP-0537949-A1 Antiproliferative derivatives of 4H-naphtho 1,2-b pyran LILLY INDUSTRIES LIMITED (GB) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 MAPT 4559/4885KMT2A 3893/4885ALDH1A1 152/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK MAPT 4458/4885KMT2A 3650/4885ALDH1A1 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.